Why Is Ocugen Stock Soaring Today?

Benzinga_recent_news03-12

Ocugen Inc (NASDAQ:OCGN) shares are surging on Wednesday afternoon after Oppenheimer analyst Leland Gershell initiated coverage with an Outperform rating and a $10 price target. Here’s what investors ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618752589?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/11/Woman-Hand-Holding-Healthcare-Medical-Ic_1.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2026-03-12 04:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618752589","market":"hk","top_or_hot":-1,"title":"Why Is Ocugen Stock Soaring Today?","media":"Benzinga_recent_news","content":"<div>\n<p>Ocugen Inc (NASDAQ:OCGN) shares are surging on Wednesday afternoon after Oppenheimer analyst Leland Gershell initiated coverage with an Outperform rating and a $10 price target. Here’s what investors ...</p>\n\n<a href=\"https://www.benzinga.com/trading-ideas/movers/26/03/51199617/why-is-ocugen-stock-soaring-today\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Is Ocugen Stock Soaring Today?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Is Ocugen Stock Soaring Today?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-12 04:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/trading-ideas/movers/26/03/51199617/why-is-ocugen-stock-soaring-today><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ocugen Inc (NASDAQ:OCGN) shares are surging on Wednesday afternoon after Oppenheimer analyst Leland Gershell initiated coverage with an Outperform rating and a $10 price target. Here’s what investors ...</p>\n\n<a href=\"https://www.benzinga.com/trading-ideas/movers/26/03/51199617/why-is-ocugen-stock-soaring-today\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4563","symbol_name":"昨日强势股","start_time":0,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/03/51199617/why-is-ocugen-stock-soaring-today","article_id":"2618752589","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/11/Woman-Hand-Holding-Healthcare-Medical-Ic_1.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/movers/26/03/51199617/why-is-ocugen-stock-soaring-today","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2618752589","pubTimestamp":1773260460,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Ocugen shares are surging Wednesday afternoon after Oppenheimer analyst Leland Gershell initiated coverage with an Outperform rating and a $10 price target.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4563":"昨日强势股","BK4139":"生物科技","BK4217":"自存仓储房地产信托","SMA":"Smartstop Self Storage REIT Inc","OCGN":"Ocugen","BK4568":"美国抗疫概念"},"translate_title":"为什么Ocugen股票今天飙升？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OCGN":1.5,"SMA":0.61},"content_text":"Ocugen Inc (NASDAQ:OCGN) shares are surging on Wednesday afternoon after Oppenheimer analyst Leland Gershell initiated coverage with an Outperform rating and a $10 price target. Here’s what investors need to know.\nIn its initiation note, Oppenheimer said it views Ocugen as an emerging gene therapy player focused on blinding eye disorders, with its lead program OCU400 seen as the main driver of potential upside.\nGershell’s thesis centers on OCU400, Ocugen's Phase 3 candidate for retinitis pigmentosa, a rare inherited eye disease affecting about 100,000 people in the U.S. \nOppenheimer said the therapy could offer a broader treatment approach than existing gene-specific options because it is designed to address multiple mutations tied to the disease. \nGershell highlighted prior Phase 1/2 data showing meaningful vision-related improvements and said the pivotal Phase 3 liMeliGhT trial has completed enrollment, with topline data expected in the first quarter of 2027.\nOppenheimer also pointed to additional upside from Ocugen's other ophthalmology pipeline programs, including OCU410ST for Stargardt disease and OCU410 for geographic atrophy. \nThe analyst said Ocugen could file three FDA applications over the next three years and argued the company's platform has the potential to reach large underserved retinal disease markets. Still, Oppenheimer noted risks tied to clinical outcomes, safety, regulation, manufacturing, competition and financing.\nOcugen is currently positioned strongly above its key moving averages, indicating bullish momentum. The stock is trading 37.1% above its 20-day SMA, 43.8% above its 50-day SMA, and a remarkable 74.2% above its 200-day SMA, suggesting a solid upward trend.\nThe golden cross in June, when the 50-day SMA crossed above the 200-day SMA, marked a significant bullish signal. This crossover often indicates a strong uptrend, and Ocugen has maintained its strength since that point.\nOver the last 12 months, Ocugen has seen an impressive gain of 316.21%. This long-term performance highlights the stock’s strong upward trajectory and suggests that traders may want to consider the potential for continued growth.\nWith the stock’s strong performance and bullish positioning above key moving averages, traders should keep an eye on momentum indicators and watch for any shifts in the current trend.\nOCGN Price Action: Ocugen shares were up 29.94% to $2.30 on Wednesday, according to Benzinga Pro data.\nPhoto: Shutterstock\nThis content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.\nTo add Benzinga News as your preferred source on Google, click here.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618752589","isCrawlerRequest":true}